Tredje AP fonden cut its stake in shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) by 24.6% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 14,973 shares of the medical equipment provider’s stock after selling 4,897 shares during the period. Tredje AP fonden’s holdings in Zimmer Biomet were worth $2,468,000 at the end of the most recent quarter.
Several other institutional investors also recently made changes to their positions in the company. Dean Capital Management boosted its position in shares of Zimmer Biomet by 1.3% in the 4th quarter. Dean Capital Management now owns 5,196 shares of the medical equipment provider’s stock valued at $778,000 after purchasing an additional 68 shares during the period. 1ST Source Bank raised its holdings in shares of Zimmer Biomet by 0.6% during the fourth quarter. 1ST Source Bank now owns 12,890 shares of the medical equipment provider’s stock valued at $1,929,000 after acquiring an additional 72 shares during the period. Baird Financial Group Inc. lifted its position in shares of Zimmer Biomet by 0.3% in the 4th quarter. Baird Financial Group Inc. now owns 28,209 shares of the medical equipment provider’s stock valued at $4,222,000 after acquiring an additional 72 shares in the last quarter. Brookstone Capital Management boosted its stake in Zimmer Biomet by 1.8% in the 4th quarter. Brookstone Capital Management now owns 4,347 shares of the medical equipment provider’s stock worth $651,000 after purchasing an additional 76 shares during the period. Finally, United Bank boosted its stake in Zimmer Biomet by 0.7% in the 4th quarter. United Bank now owns 11,031 shares of the medical equipment provider’s stock worth $1,651,000 after purchasing an additional 77 shares during the period. 86.61% of the stock is currently owned by institutional investors.
ZBH has been the subject of a number of research analyst reports. SunTrust Banks increased their target price on Zimmer Biomet from $125.00 to $132.00 and gave the company a “buy” rating in a report on Tuesday, May 12th. Canaccord Genuity increased their price objective on Zimmer Biomet from $135.00 to $137.00 and gave the stock a “buy” rating in a research note on Tuesday, May 12th. Piper Sandler lowered their target price on Zimmer Biomet from $175.00 to $160.00 and set an “overweight” rating on the stock in a research note on Monday, May 11th. Oppenheimer dropped their target price on Zimmer Biomet from $141.00 to $138.00 and set an “outperform” rating on the stock in a report on Monday, May 11th. Finally, Credit Suisse Group decreased their price target on shares of Zimmer Biomet from $125.00 to $115.00 and set an “outperform” rating for the company in a report on Friday, March 6th. Six investment analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and two have given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $146.72.
In other news, CEO Bryan C. Hanson purchased 1,000 shares of the company’s stock in a transaction dated Wednesday, May 13th. The shares were bought at an average price of $113.00 per share, with a total value of $113,000.00. Following the completion of the transaction, the chief executive officer now directly owns 54,568 shares in the company, valued at approximately $6,166,184. The purchase was disclosed in a filing with the SEC, which is available through this link. Company insiders own 0.44% of the company’s stock.
NYSE ZBH traded up $1.40 during trading on Friday, hitting $123.40. 1,009,009 shares of the company traded hands, compared to its average volume of 1,520,677. Zimmer Biomet Holdings Inc has a 12 month low of $74.37 and a 12 month high of $161.11. The business has a fifty day simple moving average of $112.68 and a 200 day simple moving average of $133.27. The company has a market capitalization of $25.18 billion, a P/E ratio of 68.18, a PEG ratio of 4.41 and a beta of 1.32. The company has a current ratio of 1.69, a quick ratio of 1.03 and a debt-to-equity ratio of 0.65.
Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Monday, May 11th. The medical equipment provider reported $1.70 EPS for the quarter, beating the Zacks’ consensus estimate of $1.53 by $0.17. Zimmer Biomet had a return on equity of 13.29% and a net margin of 4.84%. The business had revenue of $1.78 billion for the quarter, compared to analyst estimates of $1.79 billion. During the same quarter in the prior year, the firm posted $1.87 EPS. The firm’s revenue for the quarter was down 9.7% on a year-over-year basis. Equities research analysts predict that Zimmer Biomet Holdings Inc will post 4.03 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Thursday, April 30th. Shareholders of record on Friday, March 27th were issued a dividend of $0.24 per share. The ex-dividend date was Thursday, March 26th. This represents a $0.96 annualized dividend and a yield of 0.78%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 12.20%.
About Zimmer Biomet
Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.
Further Reading: What is the Book Value of a Share?
Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.